Expert Review of Neurotherapeutics , December 2012, Vol. 12, No. 12, Pages 1481-1481. more
To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Subsidized access to medical and pharmacy benefits is not a goal in and of itself; it is a means toward an end (improved health outcomes). Accordingly, the addition of an outpatient prescription drug benefit (Part D) to Medicare in 2006 will be deemed a success if it provides better, more affordable access to outpatient prescription drugs for Medicare beneficiaries and, more importantly, improves drug adherence and health outcomes, together with reducing or at least bending the cost curve by offsetting certain healthcare costs such as hospitalizations and emergency room visits. Priest and colleagues examine these claims and find suboptimal outcomes despite improved access.
| Authors: | Joshua P Cohen | |
| Journal: | Expert Review of Pharmacoeconomics & Outcomes Research | |
| Year: | 2012 | |
| DOI: | 10.1586/erp.12.25 | |
| Publication date: | 19-07-2012 |
Watchlist
This is where you can add this publication to your personal favourites.
Additional Information
Expert Review of Neurotherapeutics , December 2012, Vol. 12, No. 12, Pages 1481-1481. more
Is DaTSCAN really needed for accurate Parkinson’s disease diagnosis?
Expert Review of Neurotherapeutics , December 2012, Vol. 12, No. 12, Pages 1375-1377. more
New concepts in the early and preclinical detection of Parkinson’s disease: therapeutic implications
Parkinson’s disease is a chronic neurodegenerative disorder leading to progressive motor impairment for which there is no cure. Currently, the diagnosis is made by the presence of cardinal motor features and several associated non-motor symptoms. However, at this point, the underlying neuro ... more